

Minimal Change Disease- Pipeline Insight, 2021

<https://marketpublishers.com/r/MC3F2410A925EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: MC3F2410A925EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Minimal Change Disease – Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Minimal Change Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Minimal Change Disease Understanding

Minimal Change Disease (MCD): Overview

Minimal-change disease (MCD), also known as lipid nephrosis or nil disease, arises from a histopathologic lesion in the glomerulus and is characterized by the intense proteinuria leading to edema and intravascular volume depletion. Minimal change disease is a kidney disorder that can lead to nephrotic syndrome. In adults, the disease is usually secondary (it is caused by another disease or drug). In children, MCD is usually primary (or idiopathic, which means the exact cause is not known). The cause is unknown, but the disease may occur after or be related to: Allergic reactions, Use of NSAIDs, Tumors, Viral infections. Signs and symptoms of MCD include: Foamy urine due to large amounts of protein, Weight gain, Edema, High Cholesterol. Although Minimal Change Disease can be suspected from many of its different symptoms, the

only way to be certain of the diagnosis is with a biopsy. The treatment for nephrotic syndrome in adults with MCD is usually with a type of drug called a corticosteroid, often called steroids.

“Minimal Change Disease - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Minimal Change Disease pipeline landscape is provided which includes the disease overview and Minimal Change Disease treatment guidelines. The assessment part of the report embraces, in depth Minimal Change Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Minimal Change Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Minimal Change Disease R&D. The therapies under development are focused on novel approaches to treat/improve Minimal Change Disease.

Minimal Change Disease Emerging Drugs Chapters

This segment of the Minimal Change Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Minimal Change Disease Emerging Drugs

GFB-887: Goldfinch Bio

The Company's lead candidate, GFB-887, is a TRPC5 ion channel inhibitor, in Phase 2 development for the treatment of kidney diseases. Goldfinch Bio reported positive results from phase I trials of GFB-887, a first-in-class highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), in healthy volunteers.

Further product details are provided in the report.....

Minimal Change Disease: Therapeutic Assessment

This segment of the report provides insights about the different Minimal Change Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Minimal Change Disease

There are approx. 3+ key companies which are developing the therapies for Minimal Change Disease. The companies which have their Minimal Change Disease drug candidates in the most advanced stage, i.e. phase I include, Goldfinch Bio.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Minimal Change Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

Parenteral

Intravenous

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Minimal Change Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Minimal Change Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Minimal Change

Disease drugs.

Minimal Change Disease Report Insights

Minimal Change Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Minimal Change Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Minimal Change Disease drugs?

How many Minimal Change Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Minimal Change Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Minimal Change

Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Minimal Change Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Goldfinch Bio

Bristol-Myers Squibb

Key Products

Abatacept

GFB-887

Contents

Introduction

Executive Summary

Minimal Change Disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Minimal Change Disease – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Minimal Change Disease companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Minimal Change Disease Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

GFB-887: Goldfinch Bio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Minimal Change Disease Key Companies

Minimal Change Disease Key Products

Minimal Change Disease- Unmet Needs

Minimal Change Disease- Market Drivers and Barriers

Minimal Change Disease- Future Perspectives and Conclusion

Minimal Change Disease Analyst Views

Minimal Change Disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Minimal Change Disease
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Minimal Change Disease
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Minimal Change Disease- Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/MC3F2410A925EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC3F2410A925EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970